ALX Oncology (ALXO) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed ALX Oncology (ALXO) over the past year, gaining 75.7% versus a loss of 40.1%. Over five years, ORMP leads with a -81.0% price change compared with -98.0% for ALXO. Oramed Pharmaceuticals is the larger company by market cap ($174.7 million vs $163.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | ORMP |
|---|---|---|
| Share price | $1.18 | $4.20 |
| Market cap | $163.17M | $174.71M |
| 1-day change | +4.42% | -3.89% |
| YTD return | +4.42% | +47.37% |
| 1-year return | -40.10% | +75.73% |
| 5-year return | -98.00% | -80.96% |
| P/E ratio (TTM) | — | 1.02 |
| EPS (TTM) | $-1.13 | $4.13 |
| Dividend yield | 0.00% | 5.92% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $5.47 |
| 52-week low | $1.05 | $2.09 |
| Distance from 52-week high | -55.64% | -23.22% |
| Analyst consensus | none | none |
| Avg. price target upside | +289.83% | +66.67% |
| Average volume | 1.04M | 190.50K |
| Shares outstanding | 138.28M | 41.60M |
| Employees | 48 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed ALXO by 115.8 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.92% vs 0.00%).
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
ALXO vs ORMP FAQ
Which is bigger, ALX Oncology or Oramed Pharmaceuticals?
Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $174.71M compared with $163.17M for ALX Oncology (ALXO).
Which stock has performed better over the past year, ALXO or ORMP?
ORMP returned +75.73% over the past 12 months, compared with -40.10% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, ALX Oncology or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 5.92%, while ALX Oncology does not currently pay a regular dividend.
Are ALX Oncology and Oramed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.